Hope's Role in Cancer Management: Episode 1
OncLive
Hope's Role in Cancer Management: Episode 1
3:58
Clinical Trials in Oncology: Episode 3
OncLive
Clinical Trials in Oncology: Episode 3
4:44
Clinical Trials in Oncology: Episode 2
OncLive
Clinical Trials in Oncology: Episode 2
5:24
Behind-the-Scenes at Bridging the Gaps in Hematology
OncLive
Behind-the-Scenes at Bridging the Gaps in Hematology
2:11
Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC
OncLive
Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC
2:12
Clinical Trials in Oncology: Episode 1
OncLive
Clinical Trials in Oncology: Episode 1
4:31
Prognostic vs Predictive Factors in Oncology: Episode 3
OncLive
Prognostic vs Predictive Factors in Oncology: Episode 3
6:06
Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases
OncLive
Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases
1:29
Dr Ahluwalia on the Evolution of Precision Medicine in Oncology
OncLive
Dr Ahluwalia on the Evolution of Precision Medicine in Oncology
1:56
Prognostic vs Predictive Factors in Oncology: Episode 2
OncLive
Prognostic vs Predictive Factors in Oncology: Episode 2
4:40
Prognostic vs Predictive Factors in Oncology: Episode 1
OncLive
Prognostic vs Predictive Factors in Oncology: Episode 1
5:07
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
OncLive
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
3:02
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
OncLive
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
1:30
Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC
OncLive
Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC
2:29
Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC
OncLive
Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC
1:58
Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
OncLive
Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
1:37
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
OncLive
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
1:40
2025 ASCO GI Cancers Symposium: A Behind-the-Scenes Look With OncLive
OncLive
2025 ASCO GI Cancers Symposium: A Behind-the-Scenes Look With OncLive
1:01
A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 3
OncLive
A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 3
4:21
A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 2
OncLive
A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 2
5:35
Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed Myeloma
OncLive
Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed Myeloma
2:58
Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma
OncLive
Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma
2:35
Dr Piotrowska on Treatment Sequencing Decisions in HER2-Mutated NSCLC
OncLive
Dr Piotrowska on Treatment Sequencing Decisions in HER2-Mutated NSCLC
3:47
Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC
OncLive
Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC
2:28
Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm
OncLive
Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm
3:08
Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
OncLive
Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
1:31
A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 1
OncLive
A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 1
3:43
Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC
OncLive
Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC
4:34
Dr Ghia on a Pooled Analysis of OS Outcomes With Ibrutinib Plus Venetoclax in CLL
OncLive
Dr Ghia on a Pooled Analysis of OS Outcomes With Ibrutinib Plus Venetoclax in CLL
1:22
Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC
OncLive
Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC
3:28
Molecularly Targeted Therapies in Oncology: Episode 4
OncLive
Molecularly Targeted Therapies in Oncology: Episode 4
3:49
Dr. DeVita Discusses "The Death of Cancer"
OncLive
Dr. DeVita Discusses "The Death of Cancer"
32:59
Molecularly Targeted Therapies in Oncology: Episode 3
OncLive
Molecularly Targeted Therapies in Oncology: Episode 3
3:13
Molecularly Targeted Therapies in Oncology: Episode 2
OncLive
Molecularly Targeted Therapies in Oncology: Episode 2
3:09
Molecularly Targeted Therapies in Oncology: Episode 1
OncLive
Molecularly Targeted Therapies in Oncology: Episode 1
3:40
Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer
OncLive
Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer
3:13
Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer
OncLive
Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer
1:08
Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer
OncLive
Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer
1:05
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
OncLive
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
2:35
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
OncLive
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
3:23
Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer
OncLive
Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer
1:45
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer
OncLive
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer
0:57
ESMO 2024 Lessons in Gynecologic Oncology: Episode 3
OncLive
ESMO 2024 Lessons in Gynecologic Oncology: Episode 3
8:35
Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer
OncLive
Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer
0:39
WATCH: Dr Senan Discuss the Significance of the FDA Approval of Durvalumab for Patients With LS-SCLC
OncLive
WATCH: Dr Senan Discuss the Significance of the FDA Approval of Durvalumab for Patients With LS-SCLC
0:49
WATCH Dr Schram Discuss the FDA Approval of Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
OncLive
WATCH Dr Schram Discuss the FDA Approval of Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
0:43
ESMO 2024 Lessons in Gynecologic Oncology: Episode 2
OncLive
ESMO 2024 Lessons in Gynecologic Oncology: Episode 2
6:41
ESMO 2024 Lessons in Gynecologic Oncology: Episode 1
OncLive
ESMO 2024 Lessons in Gynecologic Oncology: Episode 1
5:21
Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract Cancer
OncLive
Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract Cancer
1:11
Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma
OncLive
Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma
1:39
Dr Reidy-Lagunes on the Evolving NET Treatment Paradigm
OncLive
Dr Reidy-Lagunes on the Evolving NET Treatment Paradigm
1:56
Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast Cancer
OncLive
Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast Cancer
1:34
Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCC
OncLive
Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCC
1:50
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
OncLive
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
23:44
Peer Review Publications in Oncology: Episode 6
OncLive
Peer Review Publications in Oncology: Episode 6
5:34
Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
OncLive
Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
1:16
Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making
OncLive
Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making
3:08
Drs Leyfman and Stearns Discuss Topics of Interest in Breast Cancer on Day 2 of The 42nd Annual CFS
OncLive
Drs Leyfman and Stearns Discuss Topics of Interest in Breast Cancer on Day 2 of The 42nd Annual CFS
6:13
Drs Harding and Leyfman Discuss Insights into HCC on Day 2 of The 42nd Annual CFS
OncLive
Drs Harding and Leyfman Discuss Insights into HCC on Day 2 of The 42nd Annual CFS
6:15
Peer Review Publications in Oncology: Episode 5
OncLive
Peer Review Publications in Oncology: Episode 5
3:21
Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC
OncLive
Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC
2:56
Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma
OncLive
Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma
1:46
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
OncLive
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
2:00
Peer Review Publications in Oncology: Episode 4
OncLive
Peer Review Publications in Oncology: Episode 4
4:59
Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCC
OncLive
Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCC
4:24
Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease Development
OncLive
Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease Development
4:45
Peer Review Publications in Oncology: Episode 3
OncLive
Peer Review Publications in Oncology: Episode 3
4:08
Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer
OncLive
Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer
3:06
Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC
OncLive
Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC
1:15
Dr Inra on the Role of the Surgeon in Early-Stage Lung Cancer
OncLive
Dr Inra on the Role of the Surgeon in Early-Stage Lung Cancer
2:04
Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC
OncLive
Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC
2:57
Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in DLBCL
OncLive
Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in DLBCL
2:16
Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer
OncLive
Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer
1:45
Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed Myeloma
OncLive
Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed Myeloma
1:46
Dr Foster on Daratumumab/Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
OncLive
Dr Foster on Daratumumab/Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
1:01
Peer Review Publications in Oncology: Episode 2
OncLive
Peer Review Publications in Oncology: Episode 2
4:09
Dr George on Other Potential Roles for Radioligand Therapy in Prostate Cancer
OncLive
Dr George on Other Potential Roles for Radioligand Therapy in Prostate Cancer
3:02
Dr Klempner on the FDA Approval of Zolbetuximab for CLDN18.2+, HER2– Gastric or GEJ Adenocarcinoma
OncLive
Dr Klempner on the FDA Approval of Zolbetuximab for CLDN18.2+, HER2– Gastric or GEJ Adenocarcinoma
2:01
Peer Review Publications in Oncology: Episode 1
OncLive
Peer Review Publications in Oncology: Episode 1
4:36
Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC
OncLive
Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC
3:05
Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia
OncLive
Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia
3:13
Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma
OncLive
Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma
1:42
Dr Hernandez-Ilizaliturri on Selecting Between CAR T-Cell Therapies for FL
OncLive
Dr Hernandez-Ilizaliturri on Selecting Between CAR T-Cell Therapies for FL
2:16
Past, Present, and Future of Precision Cancer Medicine: Episode 3
OncLive
Past, Present, and Future of Precision Cancer Medicine: Episode 3
5:04
dr-truong-on-targeted-therapy-vs-immunotherapy-in-braf-v600-positive-melanoma
OncLive
dr-truong-on-targeted-therapy-vs-immunotherapy-in-braf-v600-positive-melanoma
2:26
Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC
OncLive
Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC
1:10
Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC #lungcancer #fda
OncLive
Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC #lungcancer #fda
0:58
Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC
OncLive
Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC
4:22
Past, Present, and Future of Precision Cancer Medicine: Episode 2
OncLive
Past, Present, and Future of Precision Cancer Medicine: Episode 2
4:37
Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL
OncLive
Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL
2:21
Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL
OncLive
Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL
3:04
Dr Necchi on the Efficacy and Safety of TAR-200 Plus Cetrelimab in MIBC
OncLive
Dr Necchi on the Efficacy and Safety of TAR-200 Plus Cetrelimab in MIBC
2:37
Dr Xu on the Preliminary Efficacy of SHR-A1904 in Gastric/GEJ Cancer
OncLive
Dr Xu on the Preliminary Efficacy of SHR-A1904 in Gastric/GEJ Cancer
1:16
Past, Present, and Future of Precision Cancer Medicine: Episode 1
OncLive
Past, Present, and Future of Precision Cancer Medicine: Episode 1
4:09
2024 ESMO Congress: A Behind-the-Scenes Look With OncLive
OncLive
2024 ESMO Congress: A Behind-the-Scenes Look With OncLive
0:53
ASCO 2024 Applications in Gynecologic Oncology: Episode 4
OncLive
ASCO 2024 Applications in Gynecologic Oncology: Episode 4
1:58
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups
OncLive
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups
2:30
Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC
OncLive
Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC
2:05
Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer
OncLive
Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer
0:59